Bio-Incompatibility and Th2 Polarization during Regular Dialysis Treatment

REFERENCES

• Williams DF. A model for biocompatibility and its evaluation. J Biomed Eng 1989;11:185–191.
   PubMedGoogle Scholar
• Kaplow LS, Goffinet JA. Profound neutropenia during the early phase of hemodialysis. JAMA 1968;203:1135–1137.
   PubMed Web of Science ®Google Scholar
• Craddock PR, Fehr J, Brigham KL, Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis. N Engl J Med 1977;296:769–774.
   PubMed Web of Science ®Google Scholar
• Chenoweth DE, Cheung AK, Henderson LW. Anaphylatoxin formation during hemodialysis: Effects of different dialyzer membranes. Kidney Int 1983;24:764–769.
   PubMed Web of Science ®Google Scholar
• Luger A, Kovarik J, Stummvoll HK, Blood-membrane interaction in hemodialysis leads to increased cytokine production. Kidney Int 1987;32:84–88.
   PubMed Web of Science ®Google Scholar
• Lonnemann G, Van Der Meer JW, Cannon JG, Induction of tumor necrosis factor during extracorporeal blood purification. N Engl J Med 1987;317:963–964.
   Google Scholar
• Haeffner-Cavaillon N, Cavaillon JM, Ciancioni C, In vivo induction of interleukin-1 during hemodialysis. Kidney Int 1989;35:1212–1218.
   PubMed Web of Science ®Google Scholar
• Haeffner-Cavaillon N, Cavaillon JM, Laude M, Kazatchkine MD. C3a (C3adesArg) induces production and release of interleukin 1 by cultured human monocytes. J Immunol 1987;139:794–799.
   Google Scholar
• Laude-Sharp M, Caroff M, Simard L, Induction of IL-1 during hemodialysis: Transmembrane passage of intact endotoxins (LPS). Kidney Int 1990;38:1089–1094.
   PubMed Web of Science ®Google Scholar
• Betz M, Haensch GM, Rauterberg EW, Cuprammonium membranes stimulate interleukin-1 release and arachidonic acid metabolism in monocytes in the absence of complement. Kidney Int 1988;34:67–73.
   PubMed Web of Science ®Google Scholar
• Gejyo F, Homma N, Arakawa M. Carpal tunnel syndrome and beta 2-microglobulin-related amyloidosis in chronic hemodialysis patients. Blood Purif 1988;6:125–131.
   PubMedGoogle Scholar
• Mailloux LU, Bellucci AG, Wilkes BM, Mortality in dialysis patients: Analysis of the causes of death. Am J Kidney Dis 1991;3:326–335.
   Google Scholar
• Henderson LW, Koch KM, Dinarello CA, Shaldon S. Hemodialysis hypotension: The interleukin hypotesis. Blood Purif 1983;1:3–8.
   Google Scholar
• Dinarello CA, Mier JW. Lymphokines. N Engl J Med 1987;317:940–945.
   PubMed Web of Science ®Google Scholar
• Memoli B, Libetta C, Rampino T, Hemodialysis related induction of interleukin-6 production by peripheral blood mononuclear cells. Kidney Int 1992;42:320–326.
   PubMed Web of Science ®Google Scholar
• Hakim RM, Fearon DT, Lazarus JM. Biocompatibility of dialysis membranes: Effects of chronic complement activation. Kidney Int 1984;26:194–200.
   PubMedGoogle Scholar
• Deppisch RM, Beck W, Goehl H, Ritz E. Complement components as uremic toxins and their potential role as mediators of microinflammation. Kidney Int 2001;78:S271–S277.
   Google Scholar
• Kushner I. The phenomenon of the acute phase response. Ann NY Acad Sci 1982;389:39–48.
   PubMed Web of Science ®Google Scholar
• Steel DM, Whitehead AS. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol Today 1994;15:81–88.
   PubMedGoogle Scholar
• Ritchie DG, Fuller GM. Hepatocyte-stimulating factor: A monocyte-derived acute-phase regulatory protein. Ann N Y Acad Sci 1983;408:490–502.
   PubMedGoogle Scholar
• Wong GG, Clark SC. Multiple actions of interleukin 6 within a cytokine network. Immunol Today 1988;9:137–139.
   PubMedGoogle Scholar
• Chiu CP, Moulds C, Coffman RL, Multiple biological activities are expressed by a mouse interleukin 6 cDNA clone isolated from bone marrow stromal cells. Proc Natl Acad Sci U S A 1988;85:7099–7103.
   PubMed Web of Science ®Google Scholar
• Marinkovic S, Jahreis GP, Wong GG, Baumann H. IL-6 modulates the synthesis of a specific set of acute phase plasma proteins in vivo. J Immunol 1989;142:808–812.
   PubMed Web of Science ®Google Scholar
• Herbelin A, Ureña P, Nguyen AT, Elevated circulating levels of IL-6 in patients with chronic renal failure. Kidney Int 1991;39:954–960.
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Iwano M, Kubo A, IL-6 mRNA synthesis by peripheral blood mononuclear cells (PBMC) in patients with chronic renal failure. Clin Exp Immunol 1996;103:279–284.
   Google Scholar
• Libetta C, De Nicola L, Rampino T, Inflammatory effects of peritoneal dialysis: Evidence of systemic monocyte activation. Kidney Int 1996;49:506–511.
   PubMedGoogle Scholar
• Zaoui P, Hakim RM. The effects of the dialysis membrane on cytokine release. J Am Soc Nephrol 1994;4:1711–1718.
   PubMed Web of Science ®Google Scholar
• Yawata H, Yasukawa K, Natsuka S, Structure-function analysis of human IL-6 receptor: Dissociation of amino acid residues required for IL-6-binding and for IL-6 signal transduction through gp130. EMBO J 1993;12:1705–1712.
   PubMed Web of Science ®Google Scholar
• Murakami M, Hibi M, Nakagawa N, IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science 1993;260:1808–1810.
   PubMed Web of Science ®Google Scholar
• Memoli B, Postiglione L, Cianciaruso B, Role of different dialysis membranes in the release of interleukin-6-soluble receptor in uremic patients. Kidney Int 2000;58:417–424.
   Google Scholar
• Ramadori G, Van Damme J, Rieder H, Interleukin 6, the third mediator of acute-phase reaction, modulates hepatic protein synthesis in human and mouse. Comparison with interleukin 1 beta and tumor necrosis factor-alpha. Eur J Immunol 1988;18:1259–1264.
   PubMed Web of Science ®Google Scholar
• Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990;265:621–636.
   PubMed Web of Science ®Google Scholar
• Ramirez R, Carracedo J, Berdud I, Microinflammation in hemodialysis is related to a preactivated subset of monocytes. Hemodial Int 2006;10:S24–S27.
   Google Scholar
• Jofré R, Rodriguez-Benitez P, López-Gómez JM, Pérez-Garcia R. Inflammatory syndrome in patients on hemodialysis. J Am Soc Nephrol 2006;17:S274–S280.
   PubMedGoogle Scholar
• Nguyen-Khoa T, Massy ZA, De Bandt JP, Oxidative stress and haemodialysis: Role of inflammation and duration of dialysis treatment. Nephrol Dial Transplant 2001;16:335–340.
   PubMed Web of Science ®Google Scholar
• Witko-Sarsat V, Friedlander M, Nguyen Khoa T, Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998;161:2524–2532.
   PubMed Web of Science ®Google Scholar
• Modlinger PS, Wilcox CS, Aslam S. Nitric oxide, oxidative stress, and progression of chronic renal failure. Semin Nephrol 2004;24:354–365.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Canaud B, Eckardt KU, Oxidative stress in end-stage renal disease: An emerging threat to patient outcome. Nephrol Dial Transplant 2003;18:1272–1280.
   PubMed Web of Science ®Google Scholar
• Zager RA. Parenteral iron compounds: potent oxidants but mainstays of anemia management in chronic renal disease. Clin J Am Soc Nephrol 2006;Suppl 1:S24–S31.
   Google Scholar
• Danielski M, Ikizler TA, McMonagle E, Linkage of hypoalbuminemia, inflammation, and oxidative stress in patients receiving maintenance hemodialysis therapy. Am J Kidney Dis 2003;42:286–294.
   PubMed Web of Science ®Google Scholar
• Sanlioglu S, Williams CM, Samavati L, Lipopolysaccharide induces Rac1-dependent reactive oxygen species formation and coordinates tumor necrosis factor-alpha secretion through IKK regulation of NF-kappa B. J Biol Chem 2001;276:30188–30198.
   PubMed Web of Science ®Google Scholar
• Schwedler S, Schinzel R, Vaith P, Wanner C. Inflammation and advanced glycation end products in uremia: Simple coexistence, potentiation or causal relationship? Kidney Int 2001;59:S32–S36.
   Google Scholar
• Sebeková K, Podracká L, Heidland A, Schinzel R. Enhanced plasma levels of advanced glycation end products (AGE) and pro-inflammatory cytokines children/adolescents with chronic renal insufficiency and after renal replacement therapy by dialysis and transplantation—Are they inter-related? Clin Nephrol 2001;56:S21–S26.
   Google Scholar
• London GM, Drueke TB. Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int 1997;51:1678–1695.
   PubMed Web of Science ®Google Scholar
• Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998;9:S16–S23.
   PubMed Web of Science ®Google Scholar
• Nanayakkara PW, Gaillard CA. Vascular disease and chronic renal failure: New insights. Neth J Med 2010;68:5–14.
   PubMed Web of Science ®Google Scholar
• Moldawer LL, Copeland EM 3rd. Proinflammatory cytokines, nutricional support and the cachexia syndrome: Interactions and therapeutic options. Cancer 1997;79:1828–1839.
   PubMed Web of Science ®Google Scholar
• Himmelfarb J, Ikizler TA, Stenvinkel P, Hakim RM. The elephant in uremia: Reflections on oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002;62:1524–1538.
   PubMed Web of Science ®Google Scholar
• Ridker PM. High-sensitivity C-reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001;103:1813–1818.
   PubMed Web of Science ®Google Scholar
• Verma S, Badiwala MV, Weisel RD, C-reactive protein activates the nuclear factor-kappaB signal transduction pathway in saphenous vein endothelial cells: Implications for atherosclerosis and restenosis. J Thorac Cardiovasc Surg 2003;126:1886–1891.
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Karin M. Nuclear factor a pivotal transcription factor in chronic inflammatory disease. N Engl J Med 1997;336:1066–1071.
   PubMed Web of Science ®Google Scholar
• Brand K, Page S, Rogler G, Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest 1996;97:1715–1722.
   PubMed Web of Science ®Google Scholar
• Janssen-Heininger YMW, Poynter ME, Baeuerle PA. Recent advances towards understanding redox mechanisms in the activation of nuclear factor. Free Rad Biol Med 2000;28:1317–1327.
   PubMed Web of Science ®Google Scholar
• Furchgott R. Role of endothelium in response to vascular smooth muscle. Circ Res 1983;53:557–572.
   PubMed Web of Science ®Google Scholar
• Heitzer T, Schlinzig T, Krohn K, Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001;104:2673–2678.
   PubMed Web of Science ®Google Scholar
• Fouque D, Guebre-Egziabher F. An update on nutrition in chronic kidney disease. Int Urol Nephrol 2007;39:239–246.
   PubMed Web of Science ®Google Scholar
• Hakim RM, Levin N. Malnutrition in hemodialysis patients. Am J Kidney Dis 1993;21:125–137.
   PubMedGoogle Scholar
• Saini A, Al-Shanti N, Stewart CE. Waste management—Cytokines, growth factors and cachexia. Cytokine Growth Factor Rev 2006, 17;475–486.
   PubMed Web of Science ®Google Scholar
• Kaizu Y, Kimura M, Yoneyama T, Interleukin-6 may mediate malnutrition in chronic hemodialysis patients. Am J Kidney Dis 1998;31:93–100.
   PubMed Web of Science ®Google Scholar
• Kaysen GA, Rathore V, Shearer GC, Depner TA. Mechanism of hypoalbuminemia in hemodialysis patients. Kidney Int 1995;48:510–516.
   PubMed Web of Science ®Google Scholar
• Parker TF 3rd, Wingard RL, Husni L, Effect of the membrane biocompatibility on nutritional parameters in chronic hemodialysis patients. Kidney Int 1996;49:551–556.
   PubMed Web of Science ®Google Scholar
• Poulik MD, Bernoco M, Bernoco D, Ceppellinni R. Aggregation of HL-A antigens at the lymphocyte surface induced by antiserum to beta2-microglobulin. Science 1973;182:1352–1355.
   PubMed Web of Science ®Google Scholar
• Karlsson FA, Wibell L, Evrin PE. Beta 2-microglobulin in clinical medicine. Scan J Clin Lab Invest 1980;124:27–37.
   Google Scholar
• van Ypersele de Strihou C, Jadoul M, Malghem J, Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis. The Working Party on Dialysis Amyloidosis. Kidney Int 1991;39:1012–1019.
   PubMed Web of Science ®Google Scholar
• Zaoui PM, Stone WJ, Hakim RM. Effects of dialysis membranes on beta 2-microglobulin production and cellular expression. Kidney Int 1990;38:962–968.
   PubMedGoogle Scholar
• Nachbaur K, Troppmair J, Kotlan B, Cytokines in the control of beta-2 microglobulin release. II. In vivo studies with recombinant interferons and antigens. Immunobiology 1988;177:66–75.
   PubMed Web of Science ®Google Scholar
• Collins T, Lapierre LA, Fiers W, Recombinant human tumor necrosis factor increases mRNA levels and surface expression of HLA-A, B antigens in vascular endothelial cells and dermal fibroblast in vitro. Proc Natl Acad Sci U S A 1986;83:446–450.
   PubMed Web of Science ®Google Scholar
• Carreno MP, Rousseau Y, Poignet JL, Dissociation between beta-2 microglobulin and IL-1 production in hemodialyzed patients. Nephrol Dial Transplant 1997;12:2365–2374.
   Google Scholar
• Stevens CE, Alter HJ, Taylor PE, Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N Engl J Med 1984;311:496–501.
   PubMed Web of Science ®Google Scholar
• Raska K Jr, Raskova J, Shea SM, T cell subsets and cellular immunity in end stage renal disease. Am J Med 1983;75:734–740.
   PubMed Web of Science ®Google Scholar
• Tsakolos ND, Theoharides TC, Hendler ED, Immune defects in chronic renal impairment: Evidence for defective regulation of lymphocyte response by macrophages from patients with chronic renal impairment on haemodialysis. Clin Exp Immunol 1986;63:218–227.
   PubMed Web of Science ®Google Scholar
• Kaul H, Girndt M, Sester U, Initiation of hemodialysis treatment leads to improvement of T-cell activation in patients with end-stage renal disease. Am J Kidney Dis 2000 Apr;35:611–616.
   PubMed Web of Science ®Google Scholar
• Caligiuri MA, Zmuidzinas A, Manley TJ, Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J Exp Med 1990;171:1509–1526.
   PubMed Web of Science ®Google Scholar
• Chatenoud L, Dugas B, Beaurain G, Presence of preactivated T cells in hemodialyzed patients: Their possible role in altered immunity. Proc Natl Acad Sci U S A 1986;83:7457–7461.
   PubMed Web of Science ®Google Scholar
• Memoli B, Libetta C, De Nicola L, Hemodialysis related interleukin-2 receptor release by peripheral blood mononuclear cells. ASAIO J 1996;42:60–63.
   PubMed Web of Science ®Google Scholar
• Mosmann TR, Coffman RL. Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv Immunol 1989;46:111–147.
   PubMed Web of Science ®Google Scholar
• Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Ann Rev Immunol 1997;15:749–795.
   PubMed Web of Science ®Google Scholar
• Maggi E, Parronchi P, Manetti R, Reciprocal regulatory effects of IFN-gamma and IL-4 on the in vitro development of human Th1 and Th2 clones. J Immunol 1992;148:2142–2147.
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Schell SR, Nau G, Fitch FW. Regulation of T-cell activation: Differences among T-cell subsets. Immunol Rev 1989 Oct;111:79–110.
   PubMedGoogle Scholar
• Cledes J, Guillodo MP, Hervé JP, Hemodialysis hypereosinophilia. Contrib Nephrol 1988;62:109–117.
   Google Scholar
• Libetta C, Rampino T, Dal Canton A. Polarization of T-helper lymphocytes toward the Th2 phenotype in uremic patients. Am J Kid Dis 2001;38:286–295.
   PubMed Web of Science ®Google Scholar
• Peleman R, Wu J, Fargeas C, Delespesse G. Recombinant interleukin 4 suppresses the production of interferon gamma by human mononuclear cells. J Exp Med. 1989;170:1751–1756.
   PubMed Web of Science ®Google Scholar
• Boussiotis VA, Tsai EY, Yunis EJ, IL-10-producing T cells suppress immune responses in anergic tuberculosis patients. J Clin Invest 2000;105:1317–1325.
   PubMed Web of Science ®Google Scholar
• de Waal Malefyt R, Abrams J, Bennett B, Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991;174:1209–1220.
   PubMed Web of Science ®Google Scholar
• Seder R, Gazzinelli R, Sher A, Paul W. Interleukin-12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci U S A 1993;90:10188–10192.
   PubMed Web of Science ®Google Scholar
• Okamura H, Tsutsi H, Komatsu T, Cloning a new cytokine that induces IFN-gamma production by T cells. Nature 1995;378:88–91.
   PubMed Web of Science ®Google Scholar
• Lonnemann G, Novick D, Rubinstein M, Dinarello CA. Interleukin-18, interleukin-18 binding protein and impaired production of interferon-gamma in chronic renal failure. Clin Nephrol 2003;60:327–334.
   PubMed Web of Science ®Google Scholar
• Memoli B, Marzano L, Bisesti V, Hemodialysis-related lymphomononuclear release of interleukin-12 in patients with end-stage renal disease. J Am Soc Nephrol 1999;10:2171–176.
   Google Scholar
• Daichou Y, Kurashige S, Hashimoto S, Suzuki S. Characteristic cytokine products of Th1 and Th2 cells in hemodialysis patients. Nephron 1999;83:237–245.
   PubMed Web of Science ®Google Scholar
• Lim WH, Kireta S, Leedham E, Uremia impairs monocyte and monocyte-derived dendritic cell function in hemodialysis patients. Kidney Int 2007;72:1138–1148.
   PubMed Web of Science ®Google Scholar
• Okamura H, Tsutsui H, Kashiwamura S, Interleukin-18: A novel cytokine that augments both innate and acquired immunity. Adv Immunol 1998;70:281–312.
   PubMed Web of Science ®Google Scholar
• Libetta C, Zucchi M, Gori E, Vitamin E-loaded dialyzer resets PBMC-operated cytokine network in dialysis patients. Kidney Int 2004;65:1473–1481.
   PubMedGoogle Scholar
• Sayegh MH, Akalin E, Hancock WW, CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med 1995;181:1869–1874.
   PubMed Web of Science ®Google Scholar
• Stinn JT, Taylor MK, Becker G, Interferon-gamma-secreting T-cell populations in rejecting murine cardiac allografts: Assessment by flow cytometry. Am J Pathol 1998;153:1383–1389.
   PubMed Web of Science ®Google Scholar
• Hendrikx TK, van Gurp EA, Mol WM, End-stage renal failure and regulatory activities of CD4+CD25bright+FoxP3 +T-cells. Nephrol Dial Transplant 2009;24:1969–1978.
   PubMed Web of Science ®Google Scholar
• Libetta C, Esposito P, Sepe V, Dialysis treatment and regulatory T cells. Nephrol Dial Transplant 2010;25:1723–1727.
   PubMed Web of Science ®Google Scholar